CAL
ADPT icon

Capital Advisors Ltd’s Adaptive Biotechnologies ADPT Stock Holding History

Capital Advisors Ltd’s Portfolio ADPT Stock Details ADPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-88
Closed -$1K – 1259
2023
Q1 		$1K Hold
88
– – ﹤0.01% 968
2022
Q4 		$1K Buy
88
+55
+167% +$428 ﹤0.01% 929
2022
Q3 		$0 Buy
+33
New +$311 ﹤0.01% 1206
2022
Q1 		– Sell
-4
Closed – – 873
2021
Q4 		$0 Buy
+4
New +$123 ﹤0.01% 792

Other funds holding ADPT

Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MCMC
Matrix Capital Management Company Portsmouth, New Hampshire $46.3M AUM 114.38% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return
Sumitomo Mitsui Trust Group
Sumitomo Mitsui Trust Group Minato-Ku, Tokyo, Japan $154B AUM 29.96% 1-Year Est. Return
NAMA
Nikko Asset Management Americas New York $7.07B AUM 50.91% 1-Year Est. Return
AAP
Aristotle Atlantic Partners Sarasota, Florida $2.14B AUM 37.01% 1-Year Est. Return
BWLSA
Blue Water Life Science Advisors Larkspur, California $125M AUM 91.82% 1-Year Est. Return
PAMS
Pictet Asset Management (Switzerland) Geneva 73, Switzerland $84.3B AUM 26.5% 1-Year Est. Return

Capital Advisors Ltd's ADPT Position: Q2 2023 in Review

Capital Advisors Ltd sold out of Adaptive Biotechnologies (ADPT) in Q2 2023, closing a stake of 88 shares — an estimated $1K sold.

Capital Advisors Ltd first reported a position in ADPT in Q4 2021 and held it in 4 quarters. The position peaked at $1K in Q1 2023. 210 funds tracked by Wall St. Rank hold ADPT as of Q2 2023.

  • Capital Advisors Ltd reported no remaining Adaptive Biotechnologies position as of Q2 2023 after selling out during the quarter.
  • Capital Advisors Ltd sold 88 Adaptive Biotechnologies shares in Q2 2023, an estimated $1K.
  • Capital Advisors Ltd first reported a position in Adaptive Biotechnologies in Q4 2021 and held it in 4 quarters.
  • Capital Advisors Ltd's Adaptive Biotechnologies position peaked at $1K in Q1 2023.
  • 210 funds tracked by Wall St. Rank held Adaptive Biotechnologies as of Q2 2023.

Based on Capital Advisors Ltd's 13F filing for Q2 2023, filed 26 Jul 2023.